Leerink analyst Marc Goodman initiated coverage of Neumora Therapeutics (NMRA) with an Outperform rating and $8 price target The firm likes the company’s “diverse portfolio of opportunities.” Neumora has four specific programs “that all have a good chance of success,” the analyst tells investors in a research note. Leerink says NLRP3 inhibitors is an “intriguing novel class with a broad potential across different indications.”
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NMRA:
- Neumora Therapeutics price target raised to $6 from $5 at Mizuho
- Neumora (NMRA-511): Encouraging Early Alzheimer’s Agitation Data but Mixed V1a History and Valuation Keep Risk-Reward Balanced at Hold
- Positive Risk-Reward on Neumora as NMRA-511 Emerges as a Differentiated Therapy for Alzheimer’s Agitation, Supporting Buy Rating and $18 Target
- Neumora reports promising Phase 1b results in Alzheimer’s agitation
- Neumora Therapeutics announces results from NMRA-511 Phase 1b study